glp-1 obesity drug news updates Alarming rise in weight loss overdoses Market Overview: GLP-1 Agonists and
Description
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been studied for their cardiovascular benefits in type 2 diabetes
Dual- and multi-receptor agonists may be a novel drug class to treat obesity and type 2 diabetes mellitus with high efficacy.
Could addiction be next?
Full escalation schedules, unit conversions, weight loss data, and switching protocols.
Other adverse effects, including depression, sleep disturbances, and anxiety, have also been noted.While these side effects are usually transient, they can be bothersome enough to prompt some patients to discontinue treatment prematurely
